Having secured funding and R & D know-how in recent months, ZaiLab is currently considering spending. Approximately two months after announcing that American Depositary Receipts will provide $ 750 million to fund business development, clinical trials, commercialization and licensing agreements, Shanghai-based biopharmacy will offer them. We are ready to reveal one of the license agreements.
Zai is once again partnering with the biopharmacy MacroGenics. This collaboration will include four CD3 or CD47-based bispecific antibodies for immuno-oncology.
Zai will make a $ 25 million upfront payment to MacroGenics, based in Rockville, Maryland, and a $ 30 million equity investment in common stock. These are small compared to the up to $ 1.4 billion MacroGenics can receive in the biobags of the four programs and the additional royalties on annual net sales when the product hits the market.
The first program uses MacroGenics’ DART platform to include CD3 and research molecules that bind to private targets expressed in multiple solid tumors. The CD3 portion of the bispecific molecule is intended to minimize cytokine release syndrome. The second program revolves around the targets determined by MacroGenics.
Zai acquires commercial rights in Greater China, Japan and South Korea for the two programs, and MacroGenics retains commercial rights in all other regions. If the lead molecule achieves a predefined clinical milestone, Zai can translate regional arrangements into a global 50/50 profit share.
Scott Koenig, MD, Ph.D., CEO and President of MacroGenics. Said: statement.. “This new partnership will allow us to jointly discover, develop and deliver best-in-class potential therapies to meet the unmet medical needs of our patients.”
The two companies did not disclose details of the other two programs, in addition to Zai being an additional molecule that obtains an exclusive global license for development, manufacturing and commercialization. Each company provides intellectual property as part of its collaboration.
“MacroGenics is a great partner and one of the leading companies in immuno-oncology,” he said.
Du was mentioning First collaboration At that time, Zai paid MacroGenics the same upfront of $ 25 million for the right to develop and commercialize MacroGenics’ three immuno-oncology programs, including margetuximab (Margenza), in China. FDA Approved A drug from December last year combined with chemotherapy for adults with metastatic HER2-positive breast cancer who received two or more previous regimens. In mid-March, MacroGenics launched the drug with its commercial partner Eversana.
MacroGenics is far from the only company Zai has partnered with in recent years. The company is licensed for medicines from GlaxoSmithKline, Regeneron, Incyte, Deciphera, Entasis Therapeutics, Amgen’s Five Prime Therapeutics, Novocure, and Paratek Pharmaceuticals.
Zai’s cancer-focused partnership with MacroGenics comes quarters after Zai strengthens its leadership team to strengthen its oncology pipeline. In December, Zai said Roche veteran Alan Sandler, MD, was added as President of Oncology and Head of Global Development. Sandler was previously President and Global Head of Product Development Oncology at Genentech in Roche.
https://www.fiercebiotech.com/biotech/zai-lab-to-pay-macrogenics-25m-upfront-1-4b-potential-biobucks-for-bispecific-antibodies Zai Lab Prepays MacroGenics $ 25 Million and Pays $ 1.4 Billion Potential Bioback for Bispecific Immune Tumor Antibodies